Brief: Arrowhead Pharmaceuticals Says MHRA Grants Marketing Authorisation For REDEMPLO For FCS In Adults
27/10/2026 16:42
BRIEF-Arrowhead Pharmaceuticals Says MHRA Grants Marketing Authorisation For REDEMPLO For FCS In Adults Oct 27 (Reuters) - Arrowhead Pharmaceuticals, Inc. ARWR.O:
ADULTS LIVING WITH FAMILIAL CHYLOMICRONAEMIA SYNDROME (FCS) IN ENGLAND AND WALES HAVE REDEMPLO® (PLOZASIRAN) AS A NEW TREATMENT OPTION TO REDUCE TRIGLYCERIDES
ARROWHEAD PHARMACEUTICALS: MHRA GRANTS MARKETING AUTHORISATION FOR REDEMPLO (PLOZASIRAN) FOR FCS IN ADULTS
ARROWHEAD PHARMACEUTICALS: UK NICE RECOMMENDS NHS FUNDING FOR REDEMPLO (PLOZASIRAN) FOR GENETICALLY CONFIRMED FCS IN ADULTS
Source text: ID:nBw4Yr5da
Further company coverage: ARWR.O
(Reporting by Zakia Mariyam)
((Zakia.Mariyam@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Arrowhead Pharmaceuticals Says MHRA Grants Marketing Authorisation For REDEMPLO For FCS In Adults
Brief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal